NHS
Pan Mersey
Area Prescribing Committee

# FARICIMAB solution for injection (Vabysmo® ▼) for neovascular (wet) age-related macular degeneration

**The Pan Mersey Area Prescribing Committee recommends the prescribing of FARICIMAB solution for injection (Vabysmo ® ▼), by specialists only, for neovascular (wet) age-related macular degeneration in accordance with NICE TA800.**

**RED**

Faricimab is licensed for the treatment of neovascular (wet) age-related macular degeneration (nAMD).[1]

NICE technology appraisal (TA) 800 (29 June 2022) recommends faricimb as an option for treating wet age-related macular degeneration in adults, only if:

- the eye has a best-corrected visual acuity between 6/12 and 6/96
- there is no permanent structural damage to the central fovea
- the lesion size is 12 disc areas or less in greatest linear dimension
- there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes)[2]

Faricimab should be prescribed and administered by ophthamology specialist teams. Prescribing and monitoring should be retained by the specialist.

**Costing information**

The manufacturer has agreed to provide faricimab according to a commercial arrangement making treatment with faricimab similar in cost to treatment with other suitable treatments. If patients and their clinicians consider faricimab to be one of a range of suitable treatments (including aflibercept and ranibizumab) they should choose the least expensive treatment option, taking account of administration costs, dosage, price per dose and commercial arrangements.[2]

The NICE Resource Impact Report states that the NICE committee concluded that the total cost associated with faricimab was similar or lower than the comparator technologies.[3]

**References**


1. Roche Products Limited. Summary of Product Characteristics, Vabysmo 120 mg/mL solution for injection; May 2022. Accessed 28 June 2022.
2. National Institute for Health and Care Excellence. Technology Appraisal 800: Faricimab for treating wet age-related macular degeneration, 29 June 2022. Accessed 30 June 2022.
3. National Institute for Health and Care Excellence. Technology Appraisal 800: Resource Impact Report: Faricimab for treating wet age-related macular degeneration, 29 June 2022. Accessed 20 July 2022.


**Note**: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.